インドの診断サービス市場見通し

◆英語タイトル:Indian Diagnostic Services Market Outlook 2020
◆商品コード:RNCS60913
◆発行会社(調査会社):RNCOS
◆発行日:2016年5月
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD1,000 ⇒換算¥111,000見積依頼/購入/質問フォーム
Multi UserUSD1,600 ⇒換算¥177,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規販売代理店です。RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Diagnosis is the first step to disease management, as without accurate identification there is no possibility for accurate treatment. India is a land full of opportunities for players in the diagnostic service industry. The country has become one of the major destinations for various diagnostic services. Also, India’s thriving economy is driving urbanization and developing an expanding middle class, with rising disposable incomes to spend on healthcare.
According to RNCOS’ new research report “Indian Diagnostic Services Market Outlook 2020”, the diagnostic services market is expected to continue growing at 27.5% for next five years. This growth is likely to be driven by improving healthcare facilities, medical diagnostic and pathological laboratories, private-public projects, and the health insurance sector. Moreover, with the rise in health consciousness in the society and the rising burden of chronic diseases, this market will swell to approximately INR 860 Billion in revenues market by 2020.

Though a major portion of diagnostic business is being managed by the so called unorganized sector, the diagnostic service market is expected to become much more organized and consolidated with a lot of small and independent laboratory players becoming franchisees for the larger players. In order for clients and interested companies to enter this industry, our report provides an in-depth analysis of the cost assessment comparison of most common pathological and radiological tests among Tier I and Tier II cities.

RNCOS’ present report provides an overview of the Indian diagnostic lab services market delivering an effective overview of the market size and future forecast. In terms of services, the market is dominated by pathology services, which account for approximately 70% of the market. The report additionally investigates the current market trends and opportunities with their impact on the performance of the sector. Further, the report provides consumer behavior patterns with respect to diagnostic services. Moreover, the report also provides insights regarding the prevalence and incidences of various diseases for which the diagnostic services are widely used.

The report also covers various business models in the Indian diagnostic services market, which generally scale up the level of diagnostic services and facilitate the entry of new market players. The report effectively assesses the implementation of commonly used models, such as PPP model, hub and spoke models, and even analyzes their impact in generating revenue. Moreover, RNCOS’ industry experts prudently analyzed the regulatory and accreditation landscape with respect to setting up of diagnostic labs in Indian cities. The report, in this context, investigates into the viability of accrediting such diagnostics labs.

After an exhaustive study of the industry, the report presents a deep dive competitive landscape covering the top players along with business overview, strength-weakness analyses, recent developments, and growth strategies adopted by them to sustain their position in the Indian diagnostic services market.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. India: Macro and Demographic Indicators
3.1 Healthcare Spending
3.2 Healthcare Infrastructure
3.3 Huge Population Base
4. Market Dynamics
4.1 Drivers
4.1.1 Rising Demand of Preventive Care Diagnostics
4.1.2 Rising Burden of Chronic Diseases
4.1.3 Public – Private Partnership Models for Promoting Diagnostic Services
4.1.4 Increasing Disposable Income
4.2 Challenges
4.2.1 Low Adoption of Advanced In-Vitro Diagnostic Technologies
4.2.2 Lack of Proper Regulatory Framework
4.3 Opportunities
4.3.1 Increasing Investment by Foreign Companies
4.3.2 Rise in Medical Tourism
4.3.3 Tele-radiology: Prospective Service Facilitator for Remote Areas
4.3.4 Emerging Tier II and Tier III cities
4.4 Trends
4.4.1 Increasing Automation Driving the Indian Diagnostic Services Market
4.4.2 Inclination of Doctors towards Debt Financing
4.4.3 Home Care Health Accessibility: Gaining Consumer Acceptance
4.4.4 E-packages: New Way to Deliver Diagnostic Services
4.4.5 Gene Based Testing Methods on the Rise
5. Disease Burden
5.1 Cancer
5.2 Cardiovascular Diseases
5.3 Tuberculosis
5.4 Malaria
5.5 HIV/AIDS
5.6 Diabetes Mellitus
5.7 Dengue
6. Diagnostic Services Market: Current and Future Analysis
6.1 Pathology Services
6.1.1 Market Outlook
6.1.2 Key Segment Analysis
6.2 Radiology Services
6.2.1 Market Outlook
6.2.2 Key Segment Analysis
7. Diagnostic Services Market: Opportunity Assessment
7.1 Diagnostics Laboratories: Urban and Rural Split
7.2 Cost Assessment of Tests: Tier I and Tier II
7.2.1 Pathological Tests
7.2.2 Radiological Tests
7.3 PE Investment Landscape
8. Diagnostic Services: Business Models
8.1 Public Private Partnership (PPP)
8.1.1 Understanding of Concept: Indian Scenario
8.1.2 PPP Model in Healthcare and Diagnostic Services
8.1.3 Key Healthcare and Diagnostics PPP Projects
8.1.4 Case Study
8.2 Single Specialty Model (SSM)
8.2.1 Understanding the Concept: Indian Scenario
8.2.2 Model’s Key Advantages
8.2.3 Case Study
8.3 Hub and Spoke Model
8.3.1 Understanding of Concept: Indian Scenario
8.3.2 Model’s Key Advantages
8.3.3 Case Study
9. Consumer Behavior Research in Tier I and II
9.1 Tier I: Spending Aggressively on Diagnostic Tests
9.2 Physicians’ Referred Labs Given Highest Preference
9.3 Brand Popularity: Key Determinant for Lab Preference
9.4 Independent Labs: Popular Among Respondents
9.5 Private Lab Facilities Dominating Government Owned Centers
9.6 Medium Scale Labs: Current Choice of the Respondents
10. Regulatory Environment: Accreditation and Quality Assurance
10.1 Requirements for the Shop and Establishment Act
10.2 NABL Accreditation Mandates
10.3 NABL Accreditation Procedure
10.4 Plausible Impact of the Clinical Establishments Act, 2010
11. Competitive Landscape (Business Overview, and Strength-Weakness Analysis)
11.1 Super Religare Laboratories
11.2 Dr. Lal PathLabs
11.3 Metropolis Healthcare Limited
11.4 Thyrocare Technologies Limited
11.5 Quest Diagnostics India Private Limited,
11.6 PathCare Labs Pvt. Ltd.
11.7 Oncquest Laboratories Ltd.

List of Figures:

Figure 3-1: Healthcare Spending (US$ per head), 2015-2020
Figure 3-2: Consumer Healthcare Spending (Billion US$), 2015-2020
Figure 3-3: Share of Diagnostic Services in Total Healthcare Expenditure (%), 2015
Figure 3-4: Share of Public and Private Hospitals in Total Hospitals (%), 2015
Figure 3-5: Population (Million), 2015-2020
Figure 3-6: Population Breakup by Urban and Rural India (%), 2015
Figure 3-7: Middle Class Population (Million), 2015-2020
Figure 6-1: Share of Pathology and Radiology in Diagnostic Services Market (%), 2015
Figure 6-2: Share of Organized Diagnostic Services Market (%), 2015
Figure 6-3: Share of Organized Diagnostic Services Market (%), 2020
Figure 6-4: Diagnostic Services Market (Billion INR), 2015-2020
Figure 6-5: Pathology Services Market (Billion INR), 2015-2020
Figure 6-6: Share of Organized Pathology Services Market (%), 2020
Figure 6-7: Pathology Services Market by Segments (%), 2015
Figure 6-8: Radiology Services Market (Billion INR), 2015-2020
Figure 6-9: Share of Organized Radiology Services Market (%), 2020
Figure 6-10: Radiology Services Market by Segment (2015)
Figure 7-1: Percentage Breakup of Diagnostic Labs in Urban and Rural India
Figure 7-2: PE Investment in Key Sectors of Healthcare and Life Sciences (%), 2015
Figure 7-3: PE Investment (Million US$) and Number of Deals in Diagnostics, FY 2011-FY 2015
Figure 9-1: Tier-Wise Diagnostic Test Expenditure/Year
Figure 9-2: Consumer Preference for Physician Prescribed Lab
Figure 9-3: Factors Impacting Consumer Lab Preference
Figure 9-4: Consumer Preference by Lab Type (Independent/Hospital)
Figure 9-5: Consumer Preference by Lab Type (Government/Private)
Figure 9-6: Consumer Preference by Lab Type (Small/Medium/Large)
Figure 10-1: Flowchart for NABL Accreditation Procedure
Figure 11-1: Dr. Lal Path Labs – Breakup of Revenue by Region (%), 2015

List of Tables:

Table 3-1: Population Break-up by Age-Group (Million), 2015-2020
Table 5-1: Prevalence of Cancer (Million), 2013-2015
Table 5-2: Prevalence & Incidences of Tuberculosis (Million), 2013-2015
Table 5-3: Incidence of Malaria (Million), 2013-2015
Table 5-4: Prevalence of HIV/AIDS (Million), 2013-2015
Table 5-5: Prevalence of Diabetes (Million), 2013-2015
Table 5-6: Incidence of Dengue, 2013-2015
Table 7-1: Distribution of Diagnostic Labs in Urban Area (Class I to VI)
Table 7-2: Investigation Cost of Common Biochemical Tests in Tier I and Tier II (INR)
Table 7-3: Investigation Cost of Common Hematology Tests in Tier I and Tier II (INR)
Table 7-4: Investigation Cost of Common Immunology Tests in Tier I and Tier II (INR)
Table 7-5: Investigation Cost of Common Urinology Tests in Tier I and Tier II (INR)
Table 7-6: Investigation Cost of Common Coagulation Tests in Tier I and Tier II (INR)
Table 7-7: Investigation Cost of Common X-Ray Tests in Tier I and Tier II (INR)
Table 7-8: Investigation Cost of Common Ultrasound Tests in Tier I and Tier II (INR)
Table 7-9: Investigation Cost of Common MRI Tests in Tier I and Tier II (INR)
Table 7-10: Investigation Cost of Common CT Tests in Tier I and Tier II (INR)
Table 7-11: Investigation Cost of Common PET-CT Test in Tier I and Tier II (INR)
Table 8-1: Role of Key Stakeholders in Healthcare PPP Model
Table 8-2: Key Healthcare PPP Projects
Table 8-3: Key Diagnostic Services PPP Projects
Table 8-4: Advantages of Single Specialty Model in Diagnostic Services
Table 9-1: Characteristics of Sample Surveyed
Table 11-1: Dr. Lal Path Labs – Key Financials (Million INR), 2013-2015
Table 11-2: Quest Diagnostics – Key Financials (Million INR), 2013-2015



★調査レポート[インドの診断サービス市場見通し]販売に関する免責事項
★調査レポート[インドの診断サービス市場見通し]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆